Clinical Research Directory

Inclusion Criteria: * Able and willing to give informed consent * Probable mild cognitive impairment due to AD * Modified Hachinski Ischemia Scale (MHIS) score of \<= 4 * Mini Mental State Exam (MMSE) scores \> 21+. * Short form Geriatric Depression Scale (GDS) score of \<= 7 * Amyloid PET scan consistent with the presence of β-amyloid (A+) * Able to communicate sensations during the Exablate MRgFUS procedure * Able to attend all study visits (i.e., life expectancy of 1 year or more) Exclusion Criteria: * MRI findings: * Significant cardiac disease or unstable hemodynamic status * History of a liver disease, bleeding disorder, coagulopathy or a history of spontaneous hemorrhage * Known cerebral or systemic vasculopathy * Significant depression (GDS \> 7) and/or at potential risk of suicide (C-SSRS \> 2) * A severity score of 2 or more on any of the 'Delusions', 'Hallucinations' or 'Agitation/Aggression' subscales of the Neuropsychiatry Inventory (NPI-Q) * Known sensitivity/allergy to gadolinium(gadobutrol), DEFINITY or its components, or 18F-florbetaben. * Known hypersensitivity to DEFINITY or its components. * Any contraindications to MRI scanning * Untreated, uncontrolled sleep apnea * History of untreated or uncontrolled seizure disorder or epilepsy. * Impaired renal function * Does not have a reliable caregiver * Currently in a clinical trial involving an investigational product or non-approved use of a drug or device or in any other type of medical research. * Respiratory: chronic pulmonary disorders * History of clinically significant recent drug or alcohol use disorder who may be at higher risk for seizure or infection. * Positive human immunodeficiency virus (HIV) which can lead to increased entry of HIV into the brain parenchyma leading to HIV encephalitis. * Potential blood-borne infections, which can lead to increased entry to brain parenchyma leading to meningitis or brain abscess.